Graeme F Woodworth

Prof. Dr. Graeme F Woodworth

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2016 in Current Pharmaceutical Design
Verified
Journal Article
Open access
PDF file
DHDavid S. Hersh
David S. Hersh
AWAniket S. Wadajkar
Aniket S. Wadajkar
NRNathan B. Roberts
Nathan B. Roberts
JPJimena G. Perez
Jimena G. Perez
NCNina P. Connolly
Nina P. Connolly
AKAnthony J. Kim
Anthony J. Kim
The blood-brain barrier (BBB) poses a unique challenge for drug delivery to the central nervous system (CNS). The BBB consists of a continuous layer of specialized endothelial cells linked together by tight junctions, pericytes, nonfenestrated basal lamina, and astrocytic foot processes. This complex barrier controls and limits the systemic delivery of therapeutics to the CNS. Several innovative strategies have been explored to enhance the transport of therapeutics across the BBB, each with individual advantages and disadvantages. Ongoing advances in delivery approaches that overcome the BBB are enabling more effective therapies for CNS diseases. In this review, we discuss: (1) the physiological properties of the BBB, (2) conventional strategies to enhance paracellular and transcellular transport through the BBB, (3) emerging concepts to overcome the BBB, and (4) alternative CNS drug delivery strategies that bypass the BBB entirely. Based on these exciting advances, we anticipate that in the near future, drug delivery research efforts will lead to more effective therapeutic interventions for diseases of the CNS.

9 September 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PAPavlos Anastasiadis
Pavlos Anastasiadis
DGDheeraj Gandhi
Dheeraj Gandhi
YGYutong Guo
Yutong Guo
AAAbdul-Kareem Ahmed
Abdul-Kareem Ahmed
SBSoren M. Bentzen
Soren M. Bentzen
GWGraeme F Woodworth
Graeme F Woodworth
Pharmacological treatment of gliomas and other brain-infiltrating tumors remains challenging due to limited delivery of most therapeutics across the blood–brain barrier (BBB). Transcranial MRI-guided focused ultrasound (FUS), an emerging technology for noninvasive brain treatments, enables transient opening of the BBB through acoustic activation of circulating microbubbles. Here, we evaluate the safety and utility of transcranial microbubble-enhanced FUS (MB-FUS) for spatially targeted BBB opening in patients with infiltrating gliomas. In this Phase 0 clinical trial (NCT03322813), we conducted comparative and quantitative analyses of FUS exposures (sonications) and their effects on gliomas using MRI, histopathology, microbubble acoustic emissions (harmonic dose [HD]), and fluorescence-guided surgery metrics. Contrast-enhanced MRI and histopathology indicated safe and reproducible BBB opening in all patients. These observations occurred using a power cycling closed feedback loop controller, with the power varying by nearly an order of magnitude on average. This range underscores the need for monitoring and titrating the exposure on a patient-by-patient basis. We found a positive correlation between microbubble acoustic emissions (HD) and MR-evident BBB opening (P = 0.07) and associated interstitial changes (P < 0.01), demonstrating the unique capability to titrate the MB-FUS effects in gliomas. Importantly, we identified a 2.2-fold increase of fluorescein accumulation in MB-FUS–treated compared to untreated nonenhancing tumor tissues (P < 0.01) while accounting for vascular density. Collectively, this study demonstrates the capabilities of MB-FUS for safe, localized, controlled BBB opening and highlights the potential of this technology to improve the surgical and pharmacologic treatment of brain tumors. Significance The blood–brain barrier (BBB) is a critical obstacle to delivering most therapeutics into the brain. In this study, we report combined MRI, histological, and real-time acoustic emissions monitoring findings from a Phase 0 clinical trial examining microbubble-enhanced transcranial focused ultrasound for controlled BBB opening in patients with infiltrating gliomas. The data revealed the capability of this technology to provide safe, controlled, and tightly monitored BBB opening through the intact skull. Our findings demonstrate the capability of this technology to tune BBB opening in real-time, creating opportunities for improved treatment of brain tumors.

1 January 2016
Verified
Journal Article
Closed access
DHDavid S Hersh
David S Hersh
AWAniket S Wadajkar
Aniket S Wadajkar
NRNathan Roberts
Nathan Roberts
JPJimena G Perez
Jimena G Perez
NCNina P Connolly
Nina P Connolly
AKAnthony J Kim
Anthony J Kim

21 July 2014 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
GWGraeme F Woodworth
Graeme F Woodworth
GDGavin P. Dunn
Gavin P. Dunn
ENElizabeth A. Nance
Elizabeth A. Nance
JHJustin Hanes
Justin Hanes
HBHenry Brem
Henry Brem
There is great promise that ongoing advances in the delivery of therapeutics to the central nervous system (CNS) combined with rapidly expanding knowledge of brain tumor patho-biology will provide new, more effective therapies. Brain tumors that form from brain cells, as opposed to those that come from other parts of the body, rarely metastasize outside of the CNS. Instead, the tumor cells invade deep into the brain itself, causing disruption in brain circuits, blood vessel and blood flow changes, and tissue swelling. Patients with the most common and deadly form, glioblastoma (GBM) rarely live more than 2 years even with the most aggressive treatments and often with devastating neurological consequences. Current treatments include maximal safe surgical removal or biopsy followed by radiation and chemotherapy to address the residual tumor mass and invading tumor cells. However, delivering effective and sustained treatments to these invading cells without damaging healthy brain tissue is a major challenge and focus of the emerging fields of nanomedicine and viral and cell-based therapies. New treatment strategies, particularly those directed against the invasive component of this devastating CNS disease, are sorely needed. In this review, we (1) discuss the history and evolution of treatments for GBM, (2) define and explore three critical barriers to improving therapeutic delivery to invasive brain tumors, specifically, the neuro-vascular unit as it relates to the blood brain barrier, the extra-cellular space in regard to the brain penetration barrier, and the tumor genetic heterogeneity and instability in association with the treatment efficacy barrier, and (3) identify promising new therapeutic delivery approaches that have the potential to address these barriers and create sustained, meaningful efficacy against GBM.

18 November 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
SSScott Schoen
Scott Schoen
MKM. Sait Kilinc
M. Sait Kilinc
HLHohyun Lee
Hohyun Lee
YGYutong Guo
Yutong Guo
FDF. Levent Degertekin
F. Levent Degertekin
CACostas Arvanitis
Costas Arvanitis

1 December 2015 in Journal of Controlled Release
Verified
Journal Article
Closed access
CSCraig S. Schneider
Craig S. Schneider
ABAdip G. Bhargav
Adip G. Bhargav
JPJimena G. Perez
Jimena G. Perez
AWAniket S. Wadajkar
Aniket S. Wadajkar
JWJeffrey A. Winkles
Jeffrey A. Winkles
AKAnthony J. Kim
Anthony J. Kim